Post-transplant lymphoproliferative disease
MONDO:0019088Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)
Also known as: PTLD, post-transplant lymphoproliferative disorder
28 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Smart radiation: new trial aims to zap lingering lymphoma cells
Disease control Not yet recruitingThis study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on…
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo targets Post-Transplant cancer in early trial
Disease control Not yet recruitingThis early-phase trial is testing a combination of two drugs, loncastuximab tesirine and rituximab, as a first treatment for a rare blood cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ transplant. The study will first find the safe…
Phase: PHASE1, PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New antibody shows promise against Post-Transplant virus threat
Disease control Not yet recruitingThis phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a cancer drug stop a deadly complication in transplant patients?
Prevention Not yet recruitingThis study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…
Phase: PHASE1 • Sponsor: Jennifer Amengual • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC